KRAS and pancreatic neoplasm: Importantly, KRB-456 is effective at thwarting the in vivo growth of subcutaneous and orthotopic tumors from pancreatic cancer patients with mt KRAS G12D and G12V who have relapsed after chemotherapy and radiotherapy.